Javier Zarranz-Ventura, MD, discusses the latest real-world clinical data from SPECTRUM, the first global real-world study of aflibercept 8 mg in patients with treatment-naive and previously treated neovascular age-related macular degeneration (nAMD), including efficacy, anatomical, fluid, and safety outcomes presented at ARVO 2026.
Dr. Arshad Khanani introduces the SOL-1 phase 3 trial evaluating Axpaxli (OTX-TKI) in treatment-naïve neovascular AMD.
This video series has been produced independently by Ophthalmology Times and supported by Ocular Therapeutix. The following presentation discusses OTX-TKI - an investigational product candidate that has not been approved by the FDA or any other regulatory body
An expert discusses the prevalence and clinical impact of Demodex blepharitis across Japan and Europe, highlighting regional differences in diagnosis and awareness.
Lorraine Provencher, MD, reviews the NOVA trial which measured and validated the sensitivity of a novel VR-based wearable headset for visual field testing in glaucoma.
Dr. Marion Munk reviews clinical trials of high-dose aflibercept in neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO), providing insights and discussing the clinical implications derived from these trials.
Dr Charles Wykoff presents the latest date from the GAIL extension study evaluating pegcetacoplan for treating geographic atrophy.
Dr Arshad Khanani details the key learnings from the real-world evidence generated in the TRUCKEE and TAHOE studies following the FDA approval of faricimab.
Dr Marco Zarbin presents his talk from the 2023 ASRS annual meeting, where he explores the impact of disease activity criteria on drug durability estimations in clinical trials and includes a comparative analysis across multiple clinical trials in neovascular AMD (age-related macular degeneration).
In this Rapid Readout, Dr Paul Hahn shares his presentation from the 2023 ASRS annual meeting. This study compares the efficacy of the two FDA-approved treatments for geographic atrophy based on an anchored matching-adjusted indirect comparison of the phase 3 trials.
Dr Varun Chaudhary shares insights from his presentation at the 2023 ARVO annual meeting, highlighting key findings on personalized treatment interval dosing using faricimab.
In this Rapid Readout, Dr Jennifer Lim shares her presentation from the 2023 ARVO annual meeting, highlighting the visual and anatomic outcomes observed in clinical trials of faricimab when administered according to a personalized treatment algorithm for patients with diabetic macular edema (DME).
Dr David Almeida shares insights from his presentation at the 14th Annual Congress on Controversies in Ophthalmology (COPHy) in Lisbon, Portugal.
Anat Loewenstein, MD, MHA, discusses data from the Angiogenesis, Exudation, and Degeneration 2021 Virtual Symposium on angiopoietin-2/VEGF-A dual inhibition in the management of diabetic macular edema and exudative age-related macular degeneration.
